Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elimination of the preleukemic clone in children with Down syndrome and transient myeloproliferative disorder (TMD) to prevent AML
2006-002962-20Phase 3Completed
- Sponsor
- Hannover Medical School
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cytarabine in transient leukemia (TAM), acute megakaryoblastic leukemia (AMKL) and myelogenous leukemia, sponsored by Hannover Medical School. Primary endpoint: Primary efficacy endpoint. Started Nov 2006; status: completed.
02
Drugs
cytarabine
03
Conditions
transient leukemia (TAM)acute megakaryoblastic leukemia (AMKL)myelogenous leukemia
Beyond the preview
Go deeper on 2006-002962-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002962-20.